# Alcon

Alcon is an Asset Manager based in Fort Worth, Switzerland.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Fort Worth, Switzerland
- **Region:** Europe
- **Address:** Geneva, Switzerland
- **Founded:** 1945
- **Assets under management:** Undisclosed
- **Website:** alcon.com
- **LinkedIn:** https://www.linkedin.com/company/alcon-inc

## Regulatory record

- **Reports private funds:** No

## About

Alcon is the global leader in eye care, dedicated to helping people see brilliantly. The company was founded in 1945 by two pharmacists, Robert Alexander and William Conner. Alcon has a long history of industry firsts and commits substantially to Research and Development each year.

## Sectors

- Medical Devices
- Digital Health

## Offices

- Fort Worth, Texas, United States

## People

- David J. Endicott — Chief Executive Officer

## Questions

### What is Alcon's relationship to Novartis?

Novartis acquired Alcon in stages between 2008 and 2011. After years of evaluating the business, Novartis fully separated Alcon in April 2019 via a spin-off that distributed Alcon shares to Novartis shareholders. Alcon is now a fully independent, publicly traded company listed on the SIX Swiss Exchange and NYSE. Novartis retains no controlling interest.

### How does Alcon generate revenue?

Alcon operates across two reportable segments. The Surgical segment sells intraocular lenses, phacoemulsification equipment, consumables used in cataract and vitreoretinal surgery, and implantable glaucoma devices. The Vision Care segment sells contact lenses — including its silicon hydrogel daily disposable Dailies Total1 — and over-the-counter eye drops such as Systane. Together the segments produced roughly $13 billion in annual revenue during recent fiscal years.

### What is Alcon's M&A strategy?

Alcon acquires clinically differentiated ophthalmic technologies that strengthen its surgical and pharmaceutical offerings. The 2022 acquisition of Aerie Pharmaceuticals provided commercial-stage glaucoma drugs, while the 2024 BELKIN Vision deal added automated direct selective laser trabeculoplasty technology. Both deals filled specific portfolio gaps rather than representing broad diversification plays.

### Who makes investment and capital allocation decisions at Alcon?

Capital allocation decisions are overseen by CEO David J. Endicott and the executive leadership team, subject to board approval. The board includes members with deep experience across medtech, pharmaceuticals, and financial controls. Major strategic moves, such as the Aerie and BELKIN acquisitions, are disclosed via standard SEC and SIX regulatory filings.

### Where is Alcon headquartered?

Alcon maintains dual headquarters in Geneva, Switzerland, and Fort Worth, Texas. The Geneva office serves as the global operational headquarters, while Fort Worth retains significant commercial, R&D, and manufacturing functions. The dual structure reflects the company's Swiss incorporation and its deep historical and operational roots in the United States.

## Related profiles

- [Kinross Gold](https://altss.com/profile/kinross-gold-corp)
- [Kimberly-Clark](https://altss.com/profile/kimberly-clark-corp)

---

Last updated: 2026-07-10T19:20:04.000Z

Canonical page: https://altss.com/profile/alcon-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology